Compare Amphastar Pharmaceuticals Inc (AMPH) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Phillips 66 — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Phillips 66 trades at $191 (market cap $75.52B). The key difference: Phillips 66 is far larger — about 91.4× Amphastar Pharmaceuticals Inc's market cap, and Phillips 66 pays a 2.7% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | PSX | |
|---|---|---|
Market Cap | $826.08M | $75.52B |
Sector | Health | Energy |
52-Week High | $30.81 | $189.82 |
52-Week Low | $16.87 | $118.37 |
Enterprise Value | $1.22B | $97.49B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Phillips 66 (PSX) trades at $188.36, down 0.77% on the day, with strong technical momentum and bullish moving average signals. The stock shows solid fundamentals with a P/E of 18.6 and P/S of 0.57, while recent quarterly earnings have consistently beaten expectations. The company maintains a 14.75% ROE and recently declared a $1.27 quarterly dividend, reflecting management's confidence in cash flow stability.
PSX presents a compelling value opportunity with upside to the $196.57 consensus price target, supported by 57% analyst buy ratings. Key risks include refining margin volatility from Middle East disruptions and declining revenue trends from $170B in 2022 to $132.4B in 2025. The stock's technical overbought condition near resistance at $191 warrants caution despite positive momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
